Polypharmacy and Medication Usage Patterns in Hypertensive Patients: Findings From the Pars Cohort Study Publisher Pubmed



Zare P^{1, 2} ; Poustchi H³ ; Mohammadi Z³ ; Mesgarpour B⁴ ; Akbari M⁵ ; Kamalipour A⁶ ; Abdipourmehrian SR⁷ ; Hashemi ES¹ ; Ghamarshooshtari A^{1, 8} ; Hosseini SA⁹ ; Malekzadeh R¹⁰ ; Bazrafshan Drissi H¹¹ ; Malekzadeh F¹² ; Molavi Vardanjani H¹³ Show Affiliations
Source: Research in Social and Administrative Pharmacy Published:2024

Abstract

Polypharmacy, defined here as the concomitant use of five or more medications, is a significant health issue, particularly affecting individuals with chronic diseases like hypertension (HTN). To compare individuals with and without HTN in term of polypharmacy, and to investigate correlates of polypharmacy and medication use patterns in individuals with HTN in southwest Iran. This cross-sectional study used the baseline data of 9270 participants of the Pars Cohort Study (PCS) with a mean age of 52.6 ± 9.7 years. Poisson multivariable modeling was applied to identify correlates of polypharmacy, and Lexicomp® was used to assess drug-drug interactions. Anatomical Therapeutic Chemical classification was used to describe the pattern of medication use. The prevalence of polypharmacy in individuals without hypertension was 4.7 % (4.2%–5.2 %) vs. 23.7 % (22.1%–25.3 %) in individuals with hypertension (P < 0.001). Individuals with hypertension from middle-high socioeconomic status (SES) had a 1.51-fold higher prevalence of polypharmacy than vs. low SES. Those with more than three comorbidities had a 5.18 times higher prevalence of polypharmacy than those with isolated hypertension. Calcium channel blockers were the most common antihypertensives (20.9 %). In terms of drug-drug interactions, type C interactions were most prevalent among participants with hypertension and polypharmacy (76.0 %). Our findings imply a fairly high prevalence of polypharmacy and drug-drug interactions among individuals with hypertension; to tackle this issue, we recommend a national pharmacovigilance system, training programs for primary care physicians, public education and awareness campaigns, drug-checking campaigns, targeted screenings to alter modifiable risk factors, and the use of safe combination pills. © 2024 Elsevier Inc.